Genetic Testing Denied by Insurance? How to Appeal

Genetic testing is increasingly central to modern medicine — for cancer risk assessment, treatment selection, rare disease diagnosis, and reproductive planning. Despite ACA protections for USPSTF-recommended preventive services, insurance denials for genetic testing remain common. Understanding which type of test is at issue and which legal framework applies gives you the strongest foundation for a successful appeal.

Why Insurers Deny Genetic Testing

Not medically necessary. The insurer's utilisation reviewer determined that the test does not meet internal clinical criteria for your specific clinical profile. This determination often conflicts with NCCN, ACMG, or USPSTF guidelines that clearly indicate the test for patients with your family or personal history.

Experimental or investigational. Some genetic tests — particularly newer multi-gene panels, pharmacogenomic tests, and next-generation sequencing (NGS) panels — are classified as experimental by insurers even when they carry CLIA certification, FDA approval or clearance, and major society guideline endorsement.

Wrong CPT coding or out-of-network laboratory. Denials are sometimes administrative. Genetic tests use highly specific CPT codes, and mismatches between the code submitted and the plan's covered service list result in technical denial. Similarly, many genetic testing laboratories (Invitae, GeneDx, Myriad, Foundation Medicine) have specific network arrangements, and out-of-network laboratory status triggers coverage disputes.

Prior authorisation not obtained. Genetic testing commonly requires pre-approval. Failure to obtain authorisation before testing results in denial regardless of clinical appropriateness.

ACA Section 2713 preventive service mandate not applied. For USPSTF-recommended preventive genetic testing — particularly BRCA1/2 counselling and testing for women with qualifying family history — ACA Section 2713 (42 U.S.C. § 300gg-13) requires coverage without cost-sharing in non-grandfathered plans. Denials of USPSTF Grade B services in covered plans may violate federal law.

How to Appeal a Genetic Testing Denial

Step 1: Identify the Test Type and Applicable Coverage Standard

Different tests invoke different legal and clinical standards. BRCA1/2 testing for qualifying women: ACA Section 2713 and USPSTF Grade B recommendation. Hereditary cancer panels (MLH1, MSH2, BRCA2, PALB2, CHEK2): NCCN Genetic/Familial High-Risk Assessment guidelines. Pharmacogenomic testing: FDA companion diagnostic requirements and CPIC guidelines. Tumor NGS profiling: Medicare NCD 90.2 for Medicare beneficiaries; FDA-approved companion diagnostic (CDx) status for commercial plans. Whole exome/genome sequencing for rare disease: ACMG, AAP, and EPSDT protections for children under 21.

Step 2: Obtain Medical Necessity Documentation from Your Physician

Your appeal must include a letter from the ordering physician documenting the specific clinical indication: personal and family history details, the guideline criteria met for the test, and the clinical management implications of the test result. For BRCA testing, the letter should establish USPSTF criteria are met. For cancer panels, it should cite the specific NCCN risk category. For tumour profiling, the letter should explain the FDA companion diagnostic requirement for the targeted therapy being considered.

Step 3: Cite the Applicable Legal and Guideline Framework

For BRCA testing in qualifying women: cite ACA Section 2713, 42 U.S.C. § 300gg-13, and the USPSTF Grade B recommendation. For NCCN-indicated hereditary panels: cite NCCN Genetic/Familial High-Risk Assessment guidelines and the specific criteria your clinical presentation meets. For FDA companion diagnostics: cite the FDA CDx approval and the drug label requirement. For children on Medicaid: cite EPSDT (42 U.S.C. § 1396d(r)) requiring all medically necessary diagnostic tests for enrolled children under 21.

Step 4: Verify CPT Codes and Laboratory Network Status

Confirm that the correct CPT codes were submitted. Key codes include: BRCA sequencing — CPT 81162 (full sequence), 81163/81164 (specific variants); hereditary cancer panel — CPT 81432; tumour profiling — CPT 81445, 81455, 81479. If incorrect codes were submitted, request a corrected claim resubmission from your laboratory. For out-of-network laboratory denials, request a network adequacy exception if no in-network laboratory offers the specific test.

Step 5: Address GINA Protections and Invoke Your Appeal Rights

The Genetic Information Nondiscrimination Act (GINA) prohibits health insurers from using genetic information in coverage decisions or charging higher premiums based on genetic test results (42 U.S.C. § 2000ff et seq.). If the denial references genetic information in a discriminatory way, cite GINA explicitly. File your internal appeal within the deadline stated in the denial letter. Under 45 CFR § 147.136, you have the right to independent External Independent Review: Complete Guide" class="auto-link">external review after exhausting internal appeals.

Step 6: Submit a Complete Appeal with All Supporting Documentation

Submit your appeal before the deadline (typically 180 days for commercial plans). Include the denial letter, medical necessity letter from the ordering physician, applicable guideline citations, CPT code verification, and the laboratory's documentation of CLIA certification and any FDA clearance or approval status.

What to Include in Your Appeal

• Denial letter with the specific denial basis cited by the insurer
• Ordering physician's letter documenting the clinical indication and applicable guideline criteria
• Citation of ACA Section 2713 (for USPSTF preventive services), NCCN guidelines, or FDA CDx documentation
• CPT code verification and laboratory CLIA certification confirmation
• GINA protections citation if genetic information was improperly used in the coverage decision

Fight Back With ClaimBack

Genetic testing denials often rest on criteria more restrictive than published USPSTF, NCCN, or ACMG guidelines, or on ACA violations when preventive testing mandates are not applied. A targeted appeal citing the applicable guideline framework and legal protections gives you a strong basis for reversal. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal